AU2002365196C1 - Multimeric proteins and methods of making and using same - Google Patents

Multimeric proteins and methods of making and using same Download PDF

Info

Publication number
AU2002365196C1
AU2002365196C1 AU2002365196A AU2002365196A AU2002365196C1 AU 2002365196 C1 AU2002365196 C1 AU 2002365196C1 AU 2002365196 A AU2002365196 A AU 2002365196A AU 2002365196 A AU2002365196 A AU 2002365196A AU 2002365196 C1 AU2002365196 C1 AU 2002365196C1
Authority
AU
Australia
Prior art keywords
polypeptide
multimerization
multimeric protein
seq
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002365196A
Other languages
English (en)
Other versions
AU2002365196B8 (en
AU2002365196A1 (en
AU2002365196B2 (en
Inventor
Catherine Helen Charles
Fang Fang
Lori Allison Kohlstaedt
Guang-Xiang Luo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perlan Therapeutics Inc
Original Assignee
Perlan Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perlan Therapeutics Inc filed Critical Perlan Therapeutics Inc
Publication of AU2002365196A1 publication Critical patent/AU2002365196A1/en
Application granted granted Critical
Publication of AU2002365196B2 publication Critical patent/AU2002365196B2/en
Publication of AU2002365196B8 publication Critical patent/AU2002365196B8/en
Priority to AU2009201466A priority Critical patent/AU2009201466B2/en
Publication of AU2002365196C1 publication Critical patent/AU2002365196C1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
AU2002365196A 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same Ceased AU2002365196C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2009201466A AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30674601P 2001-07-19 2001-07-19
US60/306,746 2001-07-19
US33542501P 2001-11-30 2001-11-30
US60/335,425 2001-11-30
PCT/US2002/023003 WO2003062370A2 (en) 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2009201466A Division AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Publications (4)

Publication Number Publication Date
AU2002365196A1 AU2002365196A1 (en) 2003-09-18
AU2002365196B2 AU2002365196B2 (en) 2009-01-15
AU2002365196B8 AU2002365196B8 (en) 2009-01-29
AU2002365196C1 true AU2002365196C1 (en) 2009-08-13

Family

ID=27616555

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2002365196A Ceased AU2002365196C1 (en) 2001-07-19 2002-07-19 Multimeric proteins and methods of making and using same
AU2009201466A Ceased AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009201466A Ceased AU2009201466B2 (en) 2001-07-19 2009-04-15 Multimeric proteins and methods of making and using same

Country Status (6)

Country Link
US (3) US20030138440A1 (enExample)
EP (1) EP1578917A4 (enExample)
JP (3) JP2005522192A (enExample)
AU (2) AU2002365196C1 (enExample)
CA (2) CA2454358A1 (enExample)
WO (1) WO2003062370A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245052T3 (es) * 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
US8475789B2 (en) * 2008-01-22 2013-07-02 Multimerics Aps Products and methods to prevent infections
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
WO2013078425A1 (en) * 2011-11-22 2013-05-30 University Of Maryland, Baltimore Lambodies with high affinity and selectivity for glycans and uses therefor
US10329350B2 (en) 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
US20150038682A1 (en) * 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SG11201702688UA (en) * 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
KR102682118B1 (ko) * 2016-04-29 2024-07-08 주식회사유한양행 Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
WO2020181062A1 (en) 2019-03-06 2020-09-10 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
JP7691927B2 (ja) 2019-03-06 2025-06-12 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節抗原提示ポリペプチド及びその使用方法
FI4034170T3 (fi) 2019-10-23 2026-04-16 Cue Biopharma Inc Tgf-beta-polypeptidejä

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
CH668554A5 (de) 1984-04-09 1989-01-13 Sandoz Ag Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung.
EP0169146A3 (en) 1984-07-20 1988-07-20 Merck & Co. Inc. Monoclonal antibodies directed against the cellular receptor of human rhinovirus
US4698420A (en) * 1985-02-25 1987-10-06 Xoma Corporation Antibody hybrid molecules and process for their preparation
US5077195A (en) * 1985-03-01 1991-12-31 Board Of Reagents, The University Of Texas System Polypeptides complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known and methods of design therefor
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
ATE68968T1 (de) 1985-11-22 1991-11-15 Takeda Chemical Industries Ltd Liposomzusammensetzung.
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
JP2666345B2 (ja) 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US5284931A (en) 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5565550A (en) 1987-05-04 1996-10-15 Dana Farber Cancer Institute Antibodies to ICAM-2, and fragments thereof
ATE128727T1 (de) 1987-05-04 1995-10-15 Dana Farber Cancer Inst Inc Interzellulare adhäsions-moleküle und deren bindungsliganden.
US5273876A (en) 1987-06-26 1993-12-28 Syntro Corporation Recombinant human cytomegalovirus containing foreign gene
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ES2146572T3 (es) 1988-09-06 2000-08-16 Xoma Technology Ltd Elementos de expresion genica y la produccion de anticuerpos quimericos de raton-ser humano.
ES2077572T3 (es) 1988-09-28 1995-12-01 Dana Farber Cancer Inst Inc Moleculas de adhesion intercelular, y sus ligandos de fijacion.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
CA2045129A1 (en) 1989-02-01 1990-08-02 Alfred I. Geller Herpes simplex virus type i expression vector
US5665577A (en) 1989-02-06 1997-09-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
ES2035668T3 (es) 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. Uso de moleculas de adherencia intercelular y sus ligandos de union en el tratamiento del asma.
US5081584A (en) * 1989-03-13 1992-01-14 United States Of America Computer-assisted design of anti-peptides based on the amino acid sequence of a target peptide
EP0404003A3 (en) 1989-06-19 1991-10-16 Xoma Corporation Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
US5324510A (en) 1989-09-01 1994-06-28 Boehringer Ingelheim Pharmaceuticals, Inc. Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma
AU6663990A (en) 1989-11-13 1991-05-16 Green Cross Corporation, The Chimeric mouse-human antibodies with specificity to hiv antigens
EP0453554A4 (en) 1989-11-13 1993-02-17 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
EP0457875A4 (en) 1989-11-13 1993-03-03 Xoma Corporation Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
EP0459577A3 (en) 1990-06-01 1992-08-05 Merck & Co. Inc. Microbially expressed portions of a monoclonal antibody block rhinovirus attachment to cell receptors
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
GB9105383D0 (en) 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5223396A (en) 1991-05-03 1993-06-29 Boehringer Ingelheim Pharmaceuticals, Inc. Method for detecting organ transplant rejection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US5716805A (en) 1991-10-25 1998-02-10 Immunex Corporation Methods of preparing soluble, oligomeric proteins
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
US5330101A (en) 1992-02-06 1994-07-19 Nordson Corporation Material changeover and anti-skin over system
US6129914A (en) * 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
AU3972893A (en) 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
US6329507B1 (en) 1992-08-21 2001-12-11 The Dow Chemical Company Dimer and multimer forms of single chain polypeptides
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US5491074A (en) 1993-04-01 1996-02-13 Affymax Technologies Nv Association peptides
AU7353494A (en) 1993-11-12 1995-05-29 Case Western Reserve University Episomal expression vector for human gene therapy
US5928944A (en) 1994-02-04 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method of adenoviral-medicated cell transfection
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
JP3348204B2 (ja) 1994-04-20 2002-11-20 三菱アルミニウム株式会社 ろう粉末付長尺物の製造方法および装置
GB9409768D0 (en) 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
US5604090A (en) 1994-06-06 1997-02-18 Fred Hutchinson Cancer Research Center Method for increasing transduction of cells by adeno-associated virus vectors
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
US5693508A (en) 1994-11-08 1997-12-02 Chang; Lung-Ji Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats
US5573925A (en) 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
US5721340A (en) 1994-11-28 1998-02-24 The Wistar Institute Of Anatomy & Biology p53 proteins with altered tetramerization domains
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
JP3770333B2 (ja) 1995-03-15 2006-04-26 大日本住友製薬株式会社 組換えｄｎａウイルスおよびその製造方法
US6110456A (en) 1995-06-07 2000-08-29 Yale University Oral delivery or adeno-associated viral vectors
US5942433A (en) 1995-07-31 1999-08-24 The United States Of America As Represented By The Department Of Health And Human Services Extension of a protein-protein interaction surface to inactivate the function of a cellular protein
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997023631A2 (en) * 1995-12-22 1997-07-03 Somatogen, Inc. Globins containing binding domains
JP2000504934A (ja) * 1995-12-22 2000-04-25 バクスター バイオテク テクノロジー エス．アー．アール．エル． 結合ドメインを含むグロビン
US5861397A (en) 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US6096291A (en) 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
ES2245052T3 (es) 1997-12-01 2005-12-16 Fang Fang Anticuerpos de recombinacion multivalentes destinados para el tratamiento de infecciones debidas al rinovirus humano (hrv).
US20020165153A1 (en) 1998-04-06 2002-11-07 Peter Angel Transcription factors and their use
DE19815331A1 (de) * 1998-04-06 1999-10-14 Karlsruhe Forschzent Transkriptionsfaktoren und deren Verwendung
US5965712A (en) 1998-06-19 1999-10-12 Virginia Commonwealth University LZ-CD23 chimera for inhibition of IgE-mediated allergic disease
AU766190B2 (en) * 1998-10-16 2003-10-09 Biogen Idec Ma Inc. Interferon-beta fusion proteins and uses
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
WO2000032634A1 (en) * 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
CA2384766A1 (en) 1999-09-17 2001-03-22 Genzyme Transgenics Corporation Subunit optimized fusion proteins
US7951378B2 (en) 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
JP2005522192A (ja) 2001-07-19 2005-07-28 パーラン セラピューティクス， インコーポレイテッド マルチマータンパク質およびマルチマータンパク質を作製および使用する方法
JP4236000B2 (ja) 2003-09-25 2009-03-11 元気株式会社 ３次元画像処理装置、３次元画像処理方法及びプログラム

Also Published As

Publication number Publication date
CA2898314A1 (en) 2003-07-31
EP1578917A2 (en) 2005-09-28
EP1578917A4 (en) 2008-01-23
JP2005522192A (ja) 2005-07-28
WO2003062370A2 (en) 2003-07-31
US20130243768A1 (en) 2013-09-19
JP2013013417A (ja) 2013-01-24
JP5264518B2 (ja) 2013-08-14
US20030138440A1 (en) 2003-07-24
AU2002365196B8 (en) 2009-01-29
JP2009136292A (ja) 2009-06-25
AU2009201466A1 (en) 2009-05-07
AU2009201466B2 (en) 2012-05-03
US8394771B1 (en) 2013-03-12
CA2454358A1 (en) 2003-07-31
WO2003062370A3 (en) 2005-12-15
AU2002365196B2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
AU2009201466B2 (en) Multimeric proteins and methods of making and using same
AU2008258214B2 (en) Humanized antibodies against ICAM-1, their production and uses
AU2002365196A1 (en) Multimeric proteins and methods of making and using same
AU2002363027A1 (en) Humanized antibodies against ICAM-1, their production and uses
CN102781960B (zh) Hsa相关组合物及使用方法
EP1114161A1 (en) Immunoglobulin binding protein
AU2012207040B2 (en) Multimeric proteins and methods of making and using same
AU2013204068A1 (en) Multimeric proteins and methods of making and using same
MAHIOU et al. Soluble FasR ligand-binding domain: high-yield production of active fusion and non-fusion recombinant proteins using the baculovirus/insect cell system
HK1159139A (en) Humanized antibodies against icam-1, their production and uses
RU2821896C1 (ru) Нуклеотидная последовательность, кодирующая слитый белок, состоящий из функционального фрагмента человеческого IL-1RA и константной части тяжелой цепи человеческого IgG4
AU2013204969A1 (en) Humanized antibodies
JPWO1997042319A1 (ja) 新規Ｆａｓ抗原誘導体

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 23, NO 2, PAGE(S) 6291 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX UNDER THE NAME PERLAN THERAPEUTICS, INC., APPLICATION NO. 2002365196, UNDER INID(72), CORRECT THE CO-INVENTOR NAME TO CHARLES, CATHERINE HELEN

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAR 2009.

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 27 MAR 2009

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired